Catridecacog
From Infogalactic: the planetary knowledge core
| Clinical data | |
|---|---|
| Trade names | Tretten, NovoThirteen |
| AHFS/Drugs.com | entry |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
Injection |
| Identifiers | |
| ATC code | B02BD11 (WHO) |
Catridecacog (brand name Tretten in the US and NovoThirteen in Europe[1]) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.[2] It was brought to market by Novo Nordisk.[1]
References
- ↑ 1.0 1.1 NHS New Drugs Online Report for catridecacog Page accessed July 2, 2015
- ↑ Catridecacog: First drug to treat rare genetic blood clotting disorder. The Pharmacist February 01, 2014
- Lua error in package.lua at line 80: module 'strict' not found.
- Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
Categories:
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antihemorrhagics
- Biopharmaceuticals
- Blood and blood forming organ drug stubs
